Afficher la notice abrégée

Antipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users

dc.rights.licenseopenen_US
dc.contributor.authorMONTASTRUC, Francois
dc.contributor.authorBENARD-LARIBIERE, Anne
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorNOIZE, Pernelle
dc.contributor.authorPAMBRUN, Elodie
dc.contributor.authorDIAZ-BAZIN, F.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDAUBECH-TOURNIER, Marie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEGAUD, Bernard
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
dc.date.accessioned2020-11-24T17:23:45Z
dc.date.available2020-11-24T17:23:45Z
dc.date.issued2018-05
dc.identifier.issn1432-1041 (Electronic) 0031-6970 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/20894
dc.description.abstractEnPURPOSE: The present study was conducted to describe antipsychotic (AP) prevalent and incident use, characteristics of AP users, and their trends in the French population. METHODS: A cross-sectional study was repeated yearly from January 1, 2007 to December 31, 2013 (for prevalence analysis) or to December 31, 2012 (for incidence analysis) using the French Health Insurance reimbursement database (Echantillon Generaliste de Beneficiaires, EGB). For each year studied, prevalent and incident AP users were described in terms of age and gender overall, and according to the type of AP (FGAPs or SGAPs) used at index date. In addition, concurrent medications and comorbidities that a priori contraindicate the use of drugs having atropinic properties were researched. RESULTS: Prevalence and incidence remained relatively stable along the 2007-2013 period. Trends slightly decreased, from 2.07% (n = 10,252) to 2.05% (n = 11,015) for prevalence, and from 0.73% (n = 3461) to 0.66% (n = 3363) for incidence, especially in elderly, in contrast of children and adolescents (+ 39% for prevalence, from 184 to 271). The number of coprescribed drugs was found high (median = 5) and remained constant over time. In 2013, about 7% of prevalent AP users presented with a comorbidity increasing the risk of atropinic ADRs, and 36% used at least one concurrent atropinic drug. In incident AP users, these numbers were of 8 and 29%, respectively. CONCLUSIONS: The present study highlighted a marked shift from FGAPs toward SGAPs, as well as an increase in AP use in children and adolescents in France.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enAntipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users
dc.title.alternativeEur J Clin Pharmacolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s00228-017-2406-0en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29307053en_US
bordeaux.journalEuropean Journal of Clinical Pharmacologyen_US
bordeaux.page619-626en_US
bordeaux.volume74en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue5en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03192995
hal.version1
hal.date.transferred2021-04-08T13:01:11Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Journal%20of%20Clinical%20Pharmacology&rft.date=2018-05&rft.volume=74&rft.issue=5&rft.spage=619-626&rft.epage=619-626&rft.eissn=1432-1041%20(Electronic)%200031-6970%20(Linking)&rft.issn=1432-1041%20(Electronic)%200031-6970%20(Linking)&rft.au=MONTASTRUC,%20Francois&BENARD-LARIBIERE,%20Anne&NOIZE,%20Pernelle&PAMBRUN,%20Elodie&DIAZ-BAZIN,%20F.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée